Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-06-06
2004-06-29
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S412000, C514S414000, C514S415000, C514S419000, C514S422000, C514S825000, C514S885000, 60, 60, 60, 60
Reexamination Certificate
active
06756396
ABSTRACT:
TECHNICAL FIELD
The invention relates to compounds useful in photodynamic therapy (PDT) and related applications. In particular, it concerns ethylene glycol esters of monohydrobenzoporphyrins.
BACKGROUND ART
Photodynamic therapy (PDT) generally involves the administration of compounds that are capable of absorbing light, typically in the visible range, but also in the near ultraviolet, followed by irradiation of locations in the subject for which a toxic or inhibitory effect is desired. PDT was initially developed using hematoporphyrin and related compounds in the treatment of tumors, as it appeared that these compounds would “home” to locations containing rapidly dividing cells. The tumor could then be irradiated with light absorbed by the hematoporphyrin and destruction of the surrounding tissue resulted. PDT has since been shown to be useful for treatment of atherosclerotic plaques, restenosis, infections in the blood stream, rheumatoid arthritis, psoriasis and in the treatment of ocular conditions not necessarily limited to tumors.
U.S. Pat. No. 5,171,749 and patents issuing on related applications, U.S. Pat. Nos. 5,283,255; 5,399,583; 4,883,790; 4,920,143; and 5,095,030; all of which are incorporated herein by reference, describe and claim a class of photoactive compounds useful in PDT designated the monohydrobenzoporphyrins, or “BPDs.” This class is obtained by Diels-Alder reaction of a mono- or disubstituted alkyne with protoporphyrin-IX and the resultant compounds can further be isomerized, reduced, and/or derivatized to obtain a large class of BPDs. As disclosed in these patents, a particularly useful subclass of this group results from hydrolysis or partial hydrolysis of the ester groups of the 2-carboxyethyl side-chains on rings C and D. Esterification as protection of these groups during the Diels-Alder reaction results in initial products which contain 2-carbalkoxyethyl groups. It was found that facile hydrolysis of these esters could readily be conducted, leaving any carbalkoxy groups associated with the Diels-Alder product obtained from a dicarbalkoxyalkyne virtually completely unhydrolyzed. This resulted in four species of compounds, BPD-MA, BPD-MB, BPD-DA and BPD-DB as depicted in
FIG. 1
; this figure taken from U.S. Pat. No. 10 5,171,749. In this depiction, R
1
and R
2
are carbalkoxy groups, typically carbomethoxy or carboethoxy, and R is alkyl (1-6C).
BPD-MA was found to have particularly useful properties for PDT and is currently in clinical development. However, there remains a need for additional specific forms of photoactive agents which expand the repertoire of photoactive compounds for 15 the variety of indications to which PDT is applied, as noted above. The present invention provides compounds in which rings C and D contain ethylene glycol esters of the carboxyalkyl substituents. These compounds have pharmacokinetic properties which are advantageous in certain instances where PDT is employed.
DISCLOSURE OF THE INVENTION
The compounds of the invention are useful new additions to the repertoire of compounds that find application in photodynamic therapy and related methodologies that employ photoactive compounds. The presence of ethylene glycol esters in these molecules provides them with characteristics that permit expansion of the scope of conditions under which such photoactive compounds are employed and fine tuning of the treatment.
Thus, in one aspect, the invention is directed to compounds of the formula
and the metallated and/or labeled and or conjugated forms thereof
wherein R
1
is alkyl (1-6C), preferably methyl, n is an integer of 0-6, preferably 2, and R
2
is vinyl or a derivative thereof, preferably vinyl.
The invention also is directed to compounds of the formula
and the metallated and/or labeled and or conjugated forms thereof wherein R
1
, n, and R
2
are defined as described above. These analogs are derived from protoporphyrin III and protoporphyrin XIII respectively, in a manner similar to that in which the compounds of formulas 1 and 2 are derived from protoporphyrin IX. The invention also includes isomers of the various forms of formulas 1-4 which result from the unrearranged Diels-Alder condensation products (i.e., the 1,4-diene) as described in U.S. Pat. No. 4,883,790, incorporated herein by reference. These structures are also set forth in FIG.
14
.
In other aspects, the invention related to methods of diagnosis and treatment using the compounds of formula 1, 2, 3 or 4 or their 1,4-diene isomers, as shown in
FIG. 14
, or mixtures thereof.
REFERENCES:
patent: 4883790 (1989-11-01), Levy et al.
patent: 4920143 (1990-04-01), Levy et al.
patent: 5095030 (1992-03-01), Levy et al.
patent: 5171749 (1992-12-01), Levy et al.
patent: 5283255 (1994-02-01), Levy et al.
patent: 5399583 (1995-03-01), Levy et al.
patent: 5498710 (1996-03-01), Pandey et al.
patent: 352 076 (1990-01-01), None
patent: 9015 059 (1990-12-01), None
patent: 98/50386 (1998-11-01), None
Mosmann, T. et al.,J. Immunol. Meth.(1983) 65:55-63.
Levy, J. et al. (1996)Proceedings of the SPIE2625:86-95.
Masutani, M. et al. (1996)Nihon University Journal of Medicine38(1):5164.
Oboshi, M. et al. (1997)Transplantation63(6):810-817.
Richter, A. et al. (1990)Photochemisyrt and Photobiology52(3):495-500.
Waterfield, J. et al. (1997)Immunopharmacology and Immunotoxicology19(1):89-103.
Boch Ronald E.
Dolphin David
Hunt David W. C.
Jain Ashok
Levy Julia G.
Krass Frederick
Morrison & Foerster / LLP
QLT Inc.
LandOfFree
Ethylene glycol esters as photoactive agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ethylene glycol esters as photoactive agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ethylene glycol esters as photoactive agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3335727